Putrescine
Alternative Names: Fibrostat; Putrescine dihydrochlorideLatest Information Update: 24 Oct 2021
Price :
$50 *
At a glance
- Originator Ambrilia Biopharma
- Developer Ambrilia Biopharma; Biovail Corporation
- Class Biogenic amines; Diamines; Skin disorder therapies; Small molecules
- Mechanism of Action Transglutaminase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypertrophic scars
Most Recent Events
- 03 Mar 2006 Cellpep has merged with Procyon Biopharma to form Ambrilia Biopharma
- 20 Jan 2005 Data from a media release have been added to the adverse events and Skin disorders therapeutic trials sections
- 21 Jul 2004 Procyon Biopharma has completed enrolment in a phase IIb trial for Hypertrophic scars in the US and Canada